Mirabella Financial Services LLP Raises Stock Holdings in AbbVie Inc. $ABBV

Mirabella Financial Services LLP grew its position in AbbVie Inc. (NYSE:ABBV) by 154.7% in the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 32,899 shares of the company’s stock after acquiring an additional 19,980 shares during the quarter. AbbVie comprises approximately 0.6% of Mirabella Financial Services LLP’s portfolio, making the stock its 29th biggest position. Mirabella Financial Services LLP’s holdings in AbbVie were worth $7,602,000 at the end of the most recent quarter.

A number of other institutional investors also recently bought and sold shares of ABBV. Evolution Wealth Management Inc. purchased a new position in shares of AbbVie during the second quarter worth about $26,000. Chelsea Counsel Co. acquired a new stake in AbbVie during the 3rd quarter worth approximately $26,000. Texas Capital Bancshares Inc TX purchased a new position in shares of AbbVie in the 3rd quarter valued at approximately $31,000. Caitlin John LLC acquired a new position in shares of AbbVie in the third quarter valued at approximately $33,000. Finally, Financial Gravity Companies Inc. acquired a new position in shares of AbbVie in the second quarter valued at approximately $36,000. 70.23% of the stock is currently owned by institutional investors and hedge funds.

Insider Buying and Selling

In related news, EVP Perry C. Siatis sold 22,381 shares of the firm’s stock in a transaction that occurred on Wednesday, February 25th. The stock was sold at an average price of $230.00, for a total value of $5,147,630.00. Following the sale, the executive vice president owned 38,137 shares of the company’s stock, valued at approximately $8,771,510. This trade represents a 36.98% decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, SVP David Ryan Purdue sold 5,230 shares of the business’s stock in a transaction that occurred on Wednesday, March 4th. The shares were sold at an average price of $233.56, for a total value of $1,221,518.80. Following the transaction, the senior vice president owned 2,654 shares of the company’s stock, valued at $619,868.24. This represents a 66.34% decrease in their position. The SEC filing for this sale provides additional information. Insiders own 0.08% of the company’s stock.

Analysts Set New Price Targets

ABBV has been the subject of several recent research reports. Sanford C. Bernstein reaffirmed a “market perform” rating on shares of AbbVie in a report on Thursday, February 5th. Wall Street Zen raised shares of AbbVie from a “buy” rating to a “strong-buy” rating in a research note on Saturday, February 28th. Royal Bank Of Canada started coverage on shares of AbbVie in a research report on Tuesday, February 24th. They set an “outperform” rating and a $260.00 price objective for the company. Guggenheim reaffirmed a “buy” rating on shares of AbbVie in a report on Thursday. Finally, William Blair reiterated an “outperform” rating on shares of AbbVie in a research note on Monday, March 9th. Two investment analysts have rated the stock with a Strong Buy rating, fourteen have assigned a Buy rating and nine have assigned a Hold rating to the company. Based on data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average target price of $253.15.

AbbVie Trading Up 0.8%

ABBV stock opened at $221.54 on Tuesday. The stock’s 50 day simple moving average is $224.35 and its 200 day simple moving average is $224.89. AbbVie Inc. has a 12-month low of $164.39 and a 12-month high of $244.81. The firm has a market cap of $391.72 billion, a P/E ratio of 93.87, a P/E/G ratio of 0.76 and a beta of 0.34.

AbbVie (NYSE:ABBV) last released its quarterly earnings data on Wednesday, February 4th. The company reported $2.71 EPS for the quarter, topping analysts’ consensus estimates of $2.65 by $0.06. The firm had revenue of $16.62 billion during the quarter, compared to the consensus estimate of $16.39 billion. AbbVie had a net margin of 6.91% and a negative return on equity of 1,579.75%. The firm’s revenue was up 10.0% on a year-over-year basis. During the same quarter in the previous year, the company posted $2.16 earnings per share. AbbVie has set its FY 2026 guidance at 14.370-14.570 EPS and its Q1 2026 guidance at 2.970-3.010 EPS. On average, research analysts forecast that AbbVie Inc. will post 12.31 EPS for the current fiscal year.

AbbVie Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Friday, May 15th. Shareholders of record on Wednesday, April 15th will be issued a $1.73 dividend. The ex-dividend date of this dividend is Wednesday, April 15th. This represents a $6.92 dividend on an annualized basis and a yield of 3.1%. AbbVie’s dividend payout ratio (DPR) is currently 293.22%.

About AbbVie

AbbVie is a global, research-driven biopharmaceutical company that was created as a spin-off from Abbott Laboratories in 2013 and is headquartered in North Chicago, Illinois. The company focuses on discovering, developing and commercializing therapies for complex and often chronic medical conditions. Its operations span research and development, manufacturing, regulatory affairs and commercialization, with an emphasis on bringing specialty medicines to market across multiple therapeutic areas.

AbbVie’s product portfolio and pipeline cover several major therapeutic categories, including immunology, oncology, neuroscience, virology and women’s health.